Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Researchers are looking for new ways to treat people with endometrial cancer (EC) who
have previously received treatment with platinum based therapy (a type of chemotherapy)
and immunotherapy. Immunotherapy is a treatment that helps the immune system fight
cancer. Th...
Age: 18 years - 66+
Gender: Female
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
This is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab
Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and
Endometrial Cancer. The goal of the study is to determine the optimal dose of sacituzumab
govitecan fo...
Age: 18 years - 66+
Gender: Female
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor
has grown very large in one spot or has spread to other places in the body, it is called
advanced or metastatic cancer. Participants in this study must have head and neck
squamous...
Age: 18 years - 66+
Gender: All
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety,
tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel
fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte
antigen 4 (anti-CTL...
Age: 18 years - 66+
Gender: All
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back (recurrent) or does not respond to treatment (...
Age: 18 years - 66+
Gender: Female
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This phase II trial studies the effects of the combination of olaparib and durvalumab,
cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients
with endometrial cancer that has come back (recurrent) or does not respond to treatme...
Age: 18 years - 66+
Gender: Female